Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Aerosolized gentamicin reduces the burden of tuberculosis in a murine model.

Chad J Roy | Satheesh K Sivasubramani | Noton K Dutta | Smriti Mehra | Nadia A Golden | Stephanie Killeen | James D Talton | Badre E Hammoud | Peter J Didier | Deepak Kaushal
Antimicrobial agents and chemotherapy | 2012

Tuberculosis (TB) is a major infectious disease problem: 1.7 million people annually die due to TB. Emergence of drug-resistant Mycobacterium tuberculosis and the lack of new antibiotics have exacerbated the situation. There is an urgent need to develop or repurpose drugs against TB. We evaluated inhaled gentamicin as direct respiratory system-targeted therapy in a murine model of TB. Aerosolized-gentamicin-treated mice showed significantly reduced lung M. tuberculosis loads and fewer granulomas relative to untreated controls. These results suggest that direct delivery of antibiotics to the respiratory system may provide therapeutic benefit to conventional treatment regimes for treatment of pulmonary TB.

Pubmed ID: 22143521

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL106790
  • Agency: NCRR NIH HHS, United States
    Id: P51 RR000164
  • Agency: NIH HHS, United States
    Id: P51 OD011104
  • Agency: NIAID NIH HHS, United States
    Id: AI091457
  • Agency: NCRR NIH HHS, United States
    Id: RR026006
  • Agency: NHLBI NIH HHS, United States
    Id: HL106790
  • Agency: NIAID NIH HHS, United States
    Id: AI089323
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI089323
  • Agency: NCRR NIH HHS, United States
    Id: RR000164
  • Agency: NCRR NIH HHS, United States
    Id: P20 RR020159
  • Agency: NCRR NIH HHS, United States
    Id: R21 RR026006
  • Agency: PHS HHS, United States
    Id: HHSN27220070030C
  • Agency: NIAID NIH HHS, United States
    Id: R21 AI091457

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Tulane National Primate Research Center (tool)

RRID:SCR_008167

Center focused on understanding human health problems, including infectious diseases that require the use of nonhuman primates to develop diagnostics, therapeutics and preventive strategies. Primary research interests include developing vaccines, treatments and diagnostic tools for infectious diseases such as AIDS, tuberculosis, CMV, COVID-19, Lyme disease, and malaria. TNPRC has both biosafety level 2 and biosafety level 3 laboratories facilities to accommodate various research needs, and is the only National Primate Research Center with Regional Biosafety Laboratory.

View all literature mentions